Vertical Transmission of Hepatitis B Virus—An Update

Villa, Diana di Filippo; Navas, María Cristina

doi:10.3390/microorganisms11051140

Cited by 17 publications

(11 citation statements)

References 111 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Among the causes of cirrhosis, hepatitis B is a life-threatening liver infection and a major global health problem caused by the hepatitis B virus (HBV). It can lead to chronic infection, primarily associated with vertical transmission in African countries and sexual transmission in Western countries [12,13]. In 2015, 3.5% of the world's population was living with this chronic infection, with 68% in the Western Pacific and African regions.…”

Section: Hepatitis B Virus (Hbv)mentioning

confidence: 99%

Prevention in Hepatology

Muñoz-Restrepo,

Navas,

Daza

et al. 2024

JPM

Self Cite

View full text Add to dashboard Cite

The prevention of liver disease has improved significantly in the last few decades, to the point that it can now be considered a true success story. The wide variety of interventions, including comprehensive vaccination strategies, novel medications, lifestyle changes, and even preventive surgeries, have reduced the morbidity and mortality of chronic liver diseases. However, the prevalence of chronic liver diseases is increasing worldwide. Currently, fatty liver disease alone is estimated to be present in as much as 30% of the adult population. Furthermore, there is a trend towards increasing incidences of chronic hepatitis B, and a global lack of success in efforts to eliminate chronic hepatitis C. Thus, improving and efficiently rolling out existing and successful prevention strategies for chronic liver diseases will play an essential role in healthcare throughout the upcoming decades. In this review, we summarize the current options and concepts for preventing chronic liver diseases, highlight their limitations, and provide an outlook on probable future developments to improve awareness, integrated care, and the analysis of big data.

show abstract

Section: Hepatitis B Virus (Hbv)mentioning

confidence: 99%

Prevention in Hepatology

Muñoz-Restrepo,

Navas,

Daza

et al. 2024

JPM

Self Cite

View full text Add to dashboard Cite

show abstract

“…Therefore, implementing proper management and prevention strategies, including antiviral therapy during the third trimester of pregnancy and immunoprophylaxis for newborns, is critical in mitigating the risk of vertical transmission. These measures play a crucial role in enhancing outcomes for infants born to HBV-infected mothers [ 15 ].…”

Section: Reviewmentioning

confidence: 99%

Navigating Perinatal Challenges: A Comprehensive Review of Hepatitis B Viral Infection and Pregnancy Outcomes

Singh Thakur,

Tayade,

Batra

et al. 2024

Cureus

View full text Add to dashboard Cite

Hepatitis B viral infection poses a significant challenge during pregnancy, as the risk of vertical transmission carries serious consequences for both maternal and neonatal well-being. This comprehensive review delves into the intricacies surrounding hepatitis B infection during the perinatal period, shedding light on its impact on pregnancy outcomes and stressing the necessity of addressing it within the broader framework of perinatal care. By scrutinizing current evidence, diagnostic methodologies, management techniques, and preventive measures, this review emphasizes the urgent need for enhanced screening protocols, timely interventions, and augmented public health initiatives. Notably, key findings underscore the elevated likelihood of chronic hepatitis B virus (HBV) infection in infants and its enduring implications for the health of both mothers and newborns. The imperative call to action advocates for a multifaceted approach, engaging healthcare professionals, policymakers, and public health agencies to optimize strategies for management and prevention, thereby striving for improved outcomes for pregnant women and their infants affected by hepatitis B viral infection.

show abstract

“…The Western Pacific and African areas experience the largest proportion of HBV-related mortality (Hyun Kim and Ray Kim, 2018;Amponsah-Dacosta, 2021;Hsu et al, 2023). This scenario is further complicated by the prevalence of perinatal and vertical HBV transmission from infected mothers to their children, which maintains the infection throughout generations (di Filippo Villa and Navas, 2023;Naderi et al, 2023aNaderi et al, , 2023bNaderi et al, , 2023c. This is especially troublesome in areas with high incidence and low immunization coverage (Al-Amleh, 2020).…”

Section: Introductionmentioning

confidence: 99%

An overview of anti-Hepatitis B virus flavonoids and their mechanisms of action

Naderi,

Salavatiha,

Gogoi

et al. 2024

Front. Cell. Infect. Microbiol.

View full text Add to dashboard Cite

Flavonoids, a diverse group of polyphenolic compounds found in various plant-based foods, have garnered attention for their potential in combating Hepatitis B Virus (HBV) infection. Flavonoids have demonstrated promising anti-HBV activities by interfering with multiple stages of the HBV life cycle, making them promising candidates for novel antiviral agents. Certain plant families, such as Theaceae, Asteraceae, Lamiaceae, and Gentianaceae, are of particular interest for their flavonoid-rich members with anti-HBV activities. Evidences, both in vitro and in vivo, supports the anti-HBV potential of flavonoids. These subsets of compound exert their anti-HBV effects through various mechanisms, including inhibiting viral entry, disrupting viral replication, modulating transcription factors, enhancing the immune response, and inducing autophagy. The antioxidant properties of flavonoids play a crucial role in modulating oxidative stress associated with HBV infection. Several flavonoids like epigallocatechin gallate (EGCG), proanthocyanidin (PAC), hexamethoxyflavone, wogonin, and baicalin have shown significant anti-HBV potential, holding promise as therapeutic agents. Synergistic effects between flavonoids and existing antiviral therapies offer a promising approach to enhance antiviral efficacy and reduce drug resistance. Challenges, including limited bioavailability, translation from preclinical studies to clinical practice, and understanding precise targets, need to be addressed. Future research should focus on clinical trials, combination therapies, and the development of flavonoid derivatives with improved bioavailability, and optimizing their effectiveness in managing chronic HBV infections.

show abstract

Vertical Transmission of Hepatitis B Virus—An Update

Cited by 17 publications

References 111 publications

Prevention in Hepatology

Prevention in Hepatology

Navigating Perinatal Challenges: A Comprehensive Review of Hepatitis B Viral Infection and Pregnancy Outcomes

An overview of anti-Hepatitis B virus flavonoids and their mechanisms of action

Contact Info

Product

Resources

About